Providence Therapeutics has established a Clinical Advisory Board to advance its mRNA cancer vaccine initiatives, enhancing treatments for patients.

Research from Korea University highlights how mRNA vaccines can sustain flu-specific antibody responses for longer periods, potentially addressing vaccine effectiveness against evolving strains.

Providence Therapeutics launches the first-ever mRNA cancer vaccine trial for children with aggressive brain tumors in Australia, marking a crucial step in pediatric oncology.

GC Biopharma has secured IND approval for its COVID-19 mRNA vaccine, marking a significant milestone in vaccine development in South Korea.

GC Biopharma has submitted an IND application for its COVID-19 mRNA vaccine, GC4006A, aiming to begin Phase 1 trials in early 2026.

Everest Medicines has taken a significant step in cancer treatment with the first patient receiving EVM16, a personalized mRNA vaccine, at Peking University Cancer Hospital.

SK bioscience has initiated Phase 1/2 clinical trials of its mRNA vaccine for Japanese encephalitis, aiming for rapid pandemic response and global accessibility.

BioNet has been honored with the BARDA Patch Forward Prize for its groundbreaking microneedle mRNA vaccine technology, advancing global health solutions.

Esphera SynBio has launched a groundbreaking initiative to improve mRNA vaccines. This project introduces advanced nanomedicines for enhanced vaccine targeting and effectiveness.

SK bioscience has received approval for clinical trials of its mRNA vaccine candidate against Japanese encephalitis, aiming for swift global response.